LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

Inclusion Criteria: * Patients with either a) histologically-confirmed, advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists, or b) cytopathologically confirmed cutaneous T-cell lymphoma (CTCL) whose disease has progressed despite standard therapy or for whom no standard therapy exists. Inclusion is irrespective of stage of disease or extent of prior therapy. * World Health Organization (WHO) Performance Status of ≤ 2 * Patients must have the adequate laboratory values Exclusion Criteria: * Patients with a history of primary CNS tumors * Patients with any history of brain metastases * Patients with any peripheral neuropathy ≥ CTCAE grade 2 * Patients with unresolved diarrhea ≥ CTCAE grade 2 * Impairment of cardiac function * Impairment of gastrointestinal (GI) function or GI disease * Liver or renal disease Other protocol-defined inclusion/exclusion criteria may apply